Clinical trials: ACTH, open to volunteers
Quality of Life, Stroke, Acute
Cerebrovascular Disease: Quality of Life (CODE: QoL)
The goal of this observational study is to learn about quality of life, stress and caregiver burden in patients with stroke and their caregivers.
- Conditions
- Quality of Life, Stroke, Acute, Sexual Behavior, Stress
- Trial name
- CODE:QoL (NCT06443268)
- Testing
- questionnaire, hair samples, blood samples, clinical exam
- Where
- Switzerland
- Volunteers
- 680 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS)
IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion
The goal of this study is to learn how two treatments-adrenalectomy (surgical removal of an adrenal gland) and semaglutide (a medication used for weight management)-affect insulin resistance and cortisol regulation in adults with…
- Conditions
- Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's, Mild Autonomous Cortisol Excess
- Trial name
- IMPACT-MACS (NCT07361874)
- Testing
- Intervention 1: Adrenalectomy, Intervention 2: Semaglutide
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Texas Southwestern Medical Center
Cushing's Disease, Cushing Syndrome
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
The purpose of this study is to follow participants with Cushing's syndrome during the course of their routine care and to form a data registry to study long term participant outcomes.
- Conditions
- Cushing's Disease, Cushing Syndrome, Cushing Disease
- Trial name
- NCT03364803
- Testing
- Cushing's QoL (Quality of Life Questionnaire), Nottingham Health Profile (NHP), Hospital Anxiety and Depression Scale (HADS)
- Where
- 7 sites in United States
- Volunteers
- 300 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cushing Syndrome, Adrenal Insufficiency
Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders
This is a multicentric, prospective, intervention study on circadian genes expression in peripheral blood mononuclear cells as biomarkers of circadian rhythm derangement in patients affected by alterations of endogenous…
- Conditions
- Cushing Syndrome, Adrenal Insufficiency, Cushing Disease, Addison Disease
- Trial name
- CHROnOS (NCT04374721)
- Testing
- circadian gene expression evaluation
- Where
- Italy
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
ACTH, Cushing's Syndrome
Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome
Between 10% and 15% of patients with endogenous hypercortisolism (Cushing syndrome) have ectopic (non-pituitary) production of adrenocorticotropin hormone (ACTH) that causes cortisol excess.
- Trial name
- NCT02019706
- Testing
- DOTATATE PET-CT, F-DOPA PET CT, CT scan
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Cushing Disease, Pituitary Adenoma
FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease
The purpose of this research is to evaluate the performance [sensitivity, specificity, accuracy] of FET PET/CT imaging to detect ACTH-secreting pituitary adenoma, using operative findings and histopathology as truth standard.
- Trial name
- NCT07460232
- Testing
- Fluoro-O-(2) fluoroethyl-L-tyrosine (FET) PET
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Primary Aldosteronism, Hypertension
Overnight Dexamethasone in Primary Aldosteronism Screening
The goal of this observational study is to learn whether screening for primary aldosteronism can be improved among patients on chronic blood pressure-lowering medications by ordering intake of 1 mg of dexamethasone prior to…
- Trial name
- ODEPRASC (NCT06740838)
- Where
- Poland
- Volunteers
- 240 people
- Sponsor
- Medical University of Gdansk
Adrenal Gland Neoplasm, Hypertension
Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks
Background: The adrenal gland makes the hormone aldosterone. This helps regulate blood pressure. An adrenal gland tumor that makes too much aldosterone can cause high blood pressure and low potassium.
- Conditions
- Adrenal Gland Neoplasm, Hypertension, Bone Diseases, Metabolic, Cardiovascular Disease
- Trial name
- NCT03374215
- Where
- United States
- Volunteers
- 1,150 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Cushing Disease Due to Increased ACTH Secretion
Combination Osilodrostat and Cabergoline in Cushing's Disease
Cushing disease remains a challenging endocrine disorder in which persistent or recurrent hypercortisolism often requires medical therapy after surgery or when surgery is not feasible.
- Trial name
- COSCA-ECD (NCT07603466)
- Testing
- osilodrostat, osilodrostat and cabergoline
- Where
- 5 sites in Iraq
- Volunteers
- 50 people
- Sponsor
- University of Basrah
Cushing Syndrome
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
Multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's syndrome.
- Trial name
- NCT03708900
- Testing
- LCI699
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 12 people
- Sponsor
- RECORDATI GROUP
Cushing s Syndrome
Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's Syndrome
In previous clinical practice, 68Ga-Pentixafor PET/CT has demonstrated promising diagnostic utility in various neuroendocrine tumors by targeting CXCR4, a chemokine receptor overexpressed in several ACTH-secreting neoplasms.
- Trial name
- NCT07350707
- Testing
- 68Ga-Pentixafor
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Peking Union Medical College Hospital
Autoimmune Diseases, Dry Eye
Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
Single-site, open label pilot study of 20 autoimmune patients diagnosed with dry eye demonstrating via the proparacaine challenge some peripheral corneal pain component.
- Conditions
- Autoimmune Diseases, Dry Eye, Neurotrophic Keratitis
- Trial name
- MNK (NCT06964269)
- Testing
- Acthar Gel 80 UNT/ML Injectable Solution
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Toyos Clinic
Primary Membranous Nephropathy
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial.
- Trial name
- NCT05696613
- Testing
- SNP-ACTH (1-39) Gel, Rituximab
- Where
- 31 sites in United States, Canada and 1 more
- Volunteers
- 148 people
- Sponsor
- Cerium Pharmaceuticals, Inc.
Cocaine Use Disorder
Imaging CRF X NOP Interactions in CUD
This study uses [11C]NOP-1A positron emission tomography (PET) and a hydrocortisone challenge to image the interaction between nociceptive opioid peptide (NOP) receptors and cortisol/corticotrophin releasing factor (CRF) in…
- Trial name
- NCT05008146
- Testing
- Baseline [C-11]NOP-1A PET Scan, Hydrocortisone, Post-hydrocortisone [C-11]NOP-1A PET Scan
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Rajesh Narendran
Cushing Syndrome
Modified Desmopressin (mDesmo) Using Cold-Kit for PET/CT
The incidence of Cushing syndrome (CS) is 1.2-3.2 cases per million per year, of which adrenocorticotropic Hormone (ACTH)-dependent disease comprises approximately 70-80% of cases.
- Trial name
- Ga-68 mDesmo (NCT06962202)
- Where
- India
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Multiple Sclerosis
Acupressure in MS Patients
This study aims to evaluate the effects of acupressure therapy on patients with Multiple Sclerosis (MS). MS is a chronic autoimmune disease affecting the central nervous system, characterized by inflammation, demyelination, and…
- Trial name
- APEX-MS (NCT06755463)
- Testing
- Self-acupressure education
- Volunteers
- 82 people
- Sponsor
- Abant Izzet Baysal University
Cushing Syndrome
Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)
Cushing syndrome (CS) is an endocrine disorder caused by chronic exposure to glucocorticoid (GC) excess. Endogenous CS has an estimated incidence of 0.2 to 5.0 cases per million per year and prevalence of 39 to 79 cases per…
- Trial name
- NCT04543253
- Testing
- MUSE biofeedback
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Mayo Clinic
Adrenal Adenoma, Cushing Syndrome
A Prospective Cohort Study for Patients With Adrenal Diseases
The purpose of this study is to investigate the pathologic features, complications, and prognostic factors of functioning adrenal adenoma and suggest follow-up algorithms for adrenal incidentaloma.
- Conditions
- Adrenal Adenoma, Cushing Syndrome, Pheochromocytoma, Adrenal Incidentaloma
- Trial name
- NCT03474237
- Testing
- Hormone study and Imaging study
- Where
- South Korea
- Volunteers
- 1,500 people
- Sponsor
- Seoul National University Hospital
Cushing Disease, ACTH-producing Pituitary Tumour
Evaluation of Positron Emission Tomography (PET) With [18F]FET for the Detection of ACTH-Secreting Corticotroph Pituitary Neuroendocrine Tumors.
Cushing's disease results from adrenocorticotropic hormone (ACTH) secretion by corticotroph pituitary neuroendocrine tumors (PitNETs).
- Trial name
- PiTFET (NCT07463625)
- Testing
- Data-only evaluation of [18F]FET PET, pituitary MRI, and biomarkers
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Hospices Civils de Lyon
Cushing Disease
Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease
Supported by the pre-clinical data (summarized in Research Strategy), the investigators propose that Fimepinostat is an ideal candidate drug in the treatment and intervention of patients with Cushing Disease.
- Trial name
- NCT05971758
- Testing
- Fimepinostat
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles